Key takeaways
- Betahistine is a histamine analogue used internationally for Ménière's disease and vestibular vertigo.
- There is no FDA approved betahistine product in the United States, so compounding is the only route here.
- The largest placebo controlled trial found no difference in vertigo attack frequency between betahistine and placebo.
- It is generally well tolerated, which is part of why clinicians continue to consider it despite the trial data.
- Compounded betahistine is not FDA approved and requires a valid prescription. The prescriber decides whether it fits.
What this guide covers
Betahistine occupies an unusual position in American medicine. It is a first line therapy for Ménière's disease across much of the world, prescribed routinely in Europe and Canada for decades, and yet a US patient cannot walk into a pharmacy and fill it.
If you have a patient who learned about it from an overseas relative, or who had been taking it before moving to the States, you have probably fielded some version of the question already. Here is the full picture, including the part of the evidence that most summaries skip past.
What betahistine is
Betahistine dihydrochloride is a histamine analogue. Pharmacologically it acts as a weak agonist at H1 receptors and a considerably more potent antagonist at H3 receptors.
The proposed mechanism involves effects on inner ear microcirculation and on vestibular signaling, though the details remain incompletely settled. That uncertainty is worth holding onto, because it becomes relevant when we look at what the trials found.
Internationally it is used mainly for Ménière's disease and for vertigo of vestibular origin, typically taken orally on a daily schedule rather than as needed for an acute attack.
Why it is not on a US pharmacy shelf
Betahistine is not an FDA approved drug product in the United States. That is the short version, and it drives everything else about how a US patient can access it.
Elsewhere the story is different. Regulators in Europe, Canada and many other countries have approved betahistine products, and it appears in international clinical practice for vestibular disorders. So a patient telling you their cousin in Germany takes it every day is not confused. They are describing standard care where that cousin lives.
The gap between how a drug is treated in the US and how it is treated abroad is not always a statement about the drug. Sometimes it is a statement about regulatory history and who chose to run which trials.
Because there is no approved US product, a compounding pharmacy preparing betahistine is working under the bulk drug substance rules in section 503A of the Federal Food, Drug, and Cosmetic Act. FDA is still building the formal 503A bulks list and maintains an interim policy in the meantime, so the status of individual substances can change. Any pharmacy compounding betahistine should be confirming its current standing rather than assuming.
The evidence, including the inconvenient part
This is the section that matters most, and we are going to be direct about it.
BEMED, published in The BMJ, 2016
Incidence of vertigo attacks did not differ between the three groups. Attack rate ratios versus placebo were 1.036 for low dose and 1.012 for high dose betahistine, and results were consistent across all secondary outcomes. Treatment was well tolerated with no unexpected safety findings.
There is a second finding in that trial worth sitting with. Monthly attack rates fell substantially over the study period in every group, placebo included. Ménière's disease fluctuates, remits and relapses on its own, which makes it exceptionally difficult to judge any treatment by observation alone. A patient who starts something and feels better may be experiencing the drug, or may be experiencing the natural course of their disease.
Cochrane reviews of systemic pharmacological interventions for Ménière's disease have reached similar conclusions about the certainty of the evidence. Separately, Cochrane assessment of betahistine for tinnitus in patients without Ménière's found no clinically important difference from placebo.
What this means for how we talk about it
Nobody should be telling a patient that compounded betahistine will reduce their vertigo attacks. The best evidence available does not support that claim. What a prescriber can do is weigh a well tolerated option with a long international track record against a condition that is genuinely difficult to treat, and make an individual judgment. That is a legitimate clinical decision. It is not a marketing claim, and we are not going to dress it up as one.
Why clinicians still consider it
Given the above, it would be fair to ask why prescriptions still come to us. A few honest reasons.
Tolerability
Across trials betahistine has been well tolerated, with no unexpected safety signals. A low burden option changes the calculus when other choices carry more.
International practice
Decades of routine use abroad, and clinical experience reported by physicians who work with vestibular patients regularly.
Continuity of care
Patients who moved to the US while already established on it, and want to continue with their physician's agreement.
Limited alternatives
Ménière's has few well supported pharmacologic options, which shapes what prescribers are willing to consider.
What compounding provides
Since no manufactured US product exists, compounding is not an alternative to a commercial option here. It is the only route.
| What a prescriber specifies | What we prepare |
|---|---|
| Strength | Capsules compounded to the exact strength written, including strengths that match international dosing conventions |
| Dosage form | Most commonly oral capsules. Talk with us if a different form would suit the patient better. |
| Titration | Multiple strengths prepared when a prescriber wants to adjust over time |
| Excipient considerations | Dye or filler conscious preparation where the formulation allows and the prescriber requests it |
As a PCCA member pharmacy operating a purpose built non sterile lab in Chino, CA, we compound each preparation to the prescription we receive. We do not select the drug, the dose or the patient. That is your call.
Important regulatory information
Please read this part
Betahistine is not an FDA approved drug product in the United States. Compounded betahistine is prepared pursuant to a valid, patient specific prescription and is used off label at the prescriber's clinical discretion.
On effectiveness. The largest placebo controlled trial of betahistine in Ménière's disease found no difference in vertigo attack frequency compared with placebo. Nothing in this article claims that compounded betahistine will reduce vertigo attacks, treat Ménière's disease, or produce any particular outcome.
No promise of results. Under federal law, promotion of prescription drugs, including compounded drugs, must be truthful, non misleading and accurate. This article is written to meet that standard, which is why the trial findings appear here rather than being left out.
FDA recommends that patients talk with their health care professional about their specific circumstances before taking any medication.
For licensed prescribers. Betahistine is a histamine analogue and prescribers assess suitability individually, including in patients with asthma, peptic ulcer disease or pheochromocytoma, per international product labeling and standard references. Because no approved US product exists, prescribers and pharmacies should verify the current federal status of betahistine as a bulk drug substance. Compounded preparations are not a substitute for clinical judgment. Mixwell is a non sterile compounding pharmacy in Chino, CA.
Sending a prescription to Mixwell
- Note the strength, capsule count, and directions on a patient specific prescription.
- Fax or e prescribe to our Chino, CA pharmacy.
- Call (909) 378-7301 to confirm current availability, formulation and turnaround time. Worth calling first on this one given its regulatory status.
- Your patient can pick up in Chino, or we can deliver. We serve patients across California.
Related from Mixwell
Common questions
Why can I get betahistine in Europe but not here?
Regulators in Europe, Canada and many other countries have approved betahistine products. FDA has not, so there is no approved US product. In the United States it is available only as a compounded preparation, prepared pursuant to a prescription.
Does betahistine actually reduce vertigo attacks?
The largest placebo controlled trial, published in The BMJ in 2016, found no difference in attack frequency between betahistine and placebo over nine months. Cochrane reviews have reached similar conclusions about the certainty of the evidence. Whether to try it anyway is a clinical judgment your prescriber makes with you.
If the trial was negative, why do doctors still prescribe it?
Ménière's disease has few well supported drug options, betahistine has been well tolerated in studies, and it has a long record of routine use internationally. Some prescribers weigh those factors and choose to try it. That is a legitimate individual decision, not a claim that it is proven to work.
Is compounded betahistine FDA approved?
No. There is no FDA approved betahistine product in the United States, and compounded preparations are not FDA approved. It is prepared individually pursuant to a valid prescription and used off label at the prescriber's discretion.
What form does Mixwell prepare it in?
Most commonly oral capsules, compounded to the strength the prescription specifies. Call us if a different dosage form would suit the patient and we can discuss options.
Should I talk to my provider first?
Yes. FDA recommends that patients talk with their health care professional about their specific circumstances before taking any medication, including compounded preparations.
Does Mixwell take insurance?
We do not accept insurance. Call (909) 378-7301 and we can go over current pricing with you.
Questions about betahistine availability or formulation?
Mixwell Compounding Pharmacy
13788 Roswell Ave, Ste 158, Chino, CA 91710
PCCA Member · CA Licensed · USP <795> · Non Sterile Compounding · Delivery Across California
Call (909) 378-7301References: Adrion C, Fischer CS, Wagner J, Gürkov R, Mansmann U, Strupp M, BEMED Study Group. Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ. 2016;352:h6816. | Webster KE, et al. Systemic pharmacological interventions for Ménière's disease. Cochrane Database of Systematic Reviews. 2023. CD015171. | Wegner S, et al. Betahistine for tinnitus. Cochrane Database of Systematic Reviews. 2018. | U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, and Interim Policy on Compounding Using Bulk Drug Substances. | International betahistine product labeling for cautions and contraindications. | This article is educational information and is not a substitute for clinical judgment or medical advice, and is not a promise of results. Reviewed by the Mixwell Compounding Pharmacy compounding team, Chino, CA.